Trump May Re-Classify Marijuana Regulatory Status

Summary

President Trump is expected to reschedule cannabis from Schedule I to Schedule III as early as Wednesday, April 22, 2026 [Zhitong]. This move follows a period of regulatory stagnation within the DEA [] and aims to reclassify cannabis as a substance with accepted medical use and lower potential for abuse [][].

Impact Analysis

So Trump is finally pulling the trigger on rescheduling cannabis to Schedule III [Zhitong]. Don’t get distracted by the ‘legalization’ headline; the real story is the tax code. Moving out of Schedule I effectively kills the 280E tax burden [], which currently prevents cannabis firms from deducting standard business expenses. We’re looking at an overnight explosion in net income and free cash flow for US Multi-State Operators (MSOs) whose effective tax rates have been hovering at a ridiculous 70%+.

The timing is classic Trump—bypassing a stalled DEA review [] to deliver a win that appeals to both populist voters and the ‘states’ rights’ crowd. This isn’t just a sentiment play; it’s a fundamental valuation reset. If this goes through, the barrier for institutional capital and potential uplisting to major exchanges drops significantly. I’d be looking at the top-tier MSOs like Green Thumb or Curaleaf. The market usually treats this as a meme trade, but the cash flow delta here is very real and currently underpriced.